Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Randomized Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese

NCT05511025 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05511025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05511025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Randomized Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
September 20, 2022
Completion date
December 19, 2023
Enrollment
54 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants